Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Glucagon like peptide-2 and neoplasia; a systematic review

Research output: Contribution to journalJournal articleResearchpeer-review

  1. An update on cirrhotic cardiomyopathy

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Hepatorenal syndrome in cirrhosis: diagnostic, pathophysiological, and therapeutic aspects

    Research output: Contribution to journalReviewResearchpeer-review

  3. Advances in the treatment of portal hypertension in cirrhosis

    Research output: Contribution to journalReviewResearchpeer-review

  4. The role and advances of immunomodulator therapy for inflammatory bowel disease

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. The novel use of peptide analogs in short bowel syndrome

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Exercise-mediated improvement of depression in patients with gastro-esophageal junction cancer is linked to kynurenine metabolism

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Minimally invasive assessment of hepatic function in children with indocyanine green elimination: a validation study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

INTRODUCTION: Glucagon like peptide-2 is synthesized from enteroendocrine L cells primarily located in the ileum and large intestine. GLP-2 stimulates crypt cell proliferation, increases intestinal blood flow, enhances gut barrier function, induces mucosal healing, and exerts an anti-apoptotic effect. Due to these effects GLP-2 is used in the treatment of short bowel syndrome (SBS). Areas covered: The aim of this systematic review was to provide information on the potential risk of intestinal neoplasia in patients receiving treatment with GLP-2. The literature search was performed independently by two authors in the following databases; Pubmed, Embase, Scopus, Web of Science and Cochrane. Expert commentary: This systematic review indicated that treatment with GLP-2(1-33) up to 30 months in humans without any known pre-existing cancer did not confer an increased risk of intestinal neoplasia in patients or animals. However, due to the small amount of patients studied it is premature to reach any final conclusions about GLP-2 - induced neoplasia. GLP-2(1-33) treatment in animals with a pre-induced cancer showed that GLP-2(1-33) may promote growth of existing neoplasia.

Original languageEnglish
JournalExpert review of gastroenterology & hepatology
Volume12
Issue number3
Pages (from-to)257-264
Number of pages8
ISSN1747-4124
DOIs
Publication statusPublished - 2018

    Research areas

  • Journal Article

ID: 52744335